In trial, datopotamab deruxtecan increased progression-free survival by 2 months

MedPage Today

New York

United States

FDA Approves Datroway for Pretreated Advanced Breast Cancer

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or

Medscape

FDA Approves New ADC for HR+, HER2- Breast Cancer

The US regulator FDA has approved a new breast cancer treatment from the British AstraZeneca and the Japanese Daiichi Sankyo. It concerns a drug called Datroway, which can be used in patients with advanced breast tumors.

De Amerikaanse toezichthouder FDA heeft een nieuwe borstkankerbehandeling van het Britse AstraZeneca en het Japanse Daiichi Sankyo goedgekeurd. Het gaat om een medicijn met de naam Datroway, dat ingezet kan worden bij patiënten met gevorderde borsttumoren.

Borstkankerbehandeling AstraZeneca en Daiichi goedgekeurd in VS

rd.nl

Apeldoorn

Gelderland

Netherlands

AstraZeneca and Daiichi breast cancer treatment approved in US

Source link : https://www.newshealth.biz/health-news/fda-approves-new-adc-for-hr-her2-breast-cancer/ The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indica…

Your Blog Domain

FDA Approves New ADC for HR+, HER2- Breast Cancer – Your Blog Domain

The FDA approved datopotamab deruxtecan (Datroway) for adults with unresectable or metastatic, hormone receptor (HR)-positive/HER2-negative breast cancer who have received

Ad Fontes Media

Media Bias/Fact Check

First approval in the U.S. for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death versus chemotherapy Second DXd antibody drug conjugate approved in U.S. based on Daiichi Sankyo’s DXd technology TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patient…

pipelinereview

DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer - Pipelinereview

Daiichi Sankyo and AstraZeneca's DATROWAY receives FDA approval for HR+/HER2- metastatic breast cancer, demonstrating superior survival rates in Phase 3 trials.

stocktitan.net

FDA Approves DATROWAY: Breakthrough Breast Cancer Drug Shows 37% Risk Reduction vs Chemotherapy

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

onclive.com

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

The FDA on Friday approved datopotamab deruxtecan, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, for a subset of patients with the most common form of breast cancer, despite mixed clinical trial outcomes.

Endpoints News

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Compared with chemotherapy, Dato-DXd demonstrates favorable median progression-free survival and overall survival in a phase 3 clinical trial.

Pharmacy Times

FDA Approves Dato-DXd for Adults With Unresectable or Metastatic HR+, HER2- Breast Cancer

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

FDA Approves Datroway for Pretreated Advanced Breast Cancer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics